Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 55 to 65 Women only

Using hyperbaric oxygen therapy to improve insulin resistance in postmenopausal women

Official title: Effect of Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopausal Women

Run by Cairo University · NCT06806345 · Data updated 2026-11-12

This study is testing if hyperbaric oxygen therapy can help improve insulin resistance in postmenopausal women who are struggling with high blood sugar levels.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages55 Years to 65 Years
SexWomen only
Enrollment40 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Cairo, Cairo Governorate)
StatusRecruiting
StartedJanuary 28, 2025
Main results expectedMarch 28, 2025
Study endsApril 28, 2025
Registry record updatedFebruary 4, 2025
Trial IDNCT06806345 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are postmenopausal women aged 55-65 with insulin resistance and a BMI between 30-34.9 kg/m² who are already managing their blood glucose levels with oral hypoglycemic drugs.

Probably not a fit

Patients with chronic obstructive pulmonary disease, cardiac pacemakers, epilepsy, physical disabilities, or other ulcer-causing disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of hyperbaric oxygen therapy on insulin resistance in postmenopausal women aged 55-65 with a BMI of 30-34.9 kg/m². Participants will receive hyperbaric oxygen therapy alongside hypoglycemic drugs to assess improvements in blood glucose levels and overall function. The study aims to identify clinical predictors that could enhance treatment efficiency and prevent complications associated with insulin resistance. By focusing on this demographic, the research seeks to address a significant public health issue in Egypt related to diabetes and cardiovascular diseases.

Why it matters

Potential benefit: If successful, this therapy could provide a novel treatment option for managing insulin resistance and improving the quality of life for postmenopausal women.

How similar studies have gone: While hyperbaric oxygen therapy has shown promise in various conditions, this specific application for insulin resistance in postmenopausal women is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* A)Inclusion Criteria

  * All females were clinically diagnosed with Postmenopausal Insulin resistance.
  * Their ages were ranged from 55-65 years old.
  * Their BMI was 30-34.9 kg/m².
  * All patients should had controlled blood glucose levels by oral hypoglycemic drugs.
  * All patients should had cardiac Ejection Fraction \>or =50%.
  * Their Chest X-ray reported normal.
  * Their Ear ,nose , thorax will be clinically evaluated by a specialized ENT physician to ensure fitting for hyperbaric chamber
  * Voluntary acceptance of participation in the study .

B)Exclusion Criteria:

Participants will be excluded if they have :

* Chronic obstructive pulmonary disease.
* Cardiac pacemakers.
* Epileptic fits.
* Physically disable .
* Any disorder that lead to ulcers other than diabetes such as ahistory of chronic peripheral arterial disease.

Exclusion Criteria:

\-

Where it's running

  • Kobry el koba military complex
    Cairo, Cairo Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.